# 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

> **NCT01216644** · PHASE2,PHASE3 · COMPLETED · sponsor: **Krankenhaus Nordwest** · enrollment: 716 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel
- **DRUG:** Epirubicin
- **DRUG:** Cisplatin
- **DRUG:** 5-fluorouracil

## Key facts

- **NCT ID:** NCT01216644
- **Lead sponsor:** Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2017-03
- **Final completion:** 2019-05
- **Target enrollment:** 716 (ACTUAL)
- **Last updated:** 2019-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01216644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01216644, "5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01216644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*